|
Iris Oifigiúil |
GA Sraith C |
|
C/2023/298 |
31.10.2023 |
Achoimre ar chinntí an Aontais Eorpaigh maidir le húdaruithe margaíochta i ndáil le táirgí íocshláinte ó 1 Meán Fómhair 2023 go dtí 30 Meán Fómhair 2023
(Arna fhoilsiú de bhun Airteagal 13 nó Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle (1) nó Airteagal 5 de Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle (2))
(C/2023/298)
— Údarú margaíochta a eisiúint (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
ANI (an tAinm Neamhdhílseánaigh Idirnáisiúnta) |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Foirm chógaisíochta |
An Cód CAT (an Cód Ceimiceach Teiripeach Anatamaíoch) |
Dáta an fhógra |
||
|
15.9.2023 |
Apretude |
cabotegravir |
|
EU/1/23/1760 |
Fuaidreán ar scaoileadh fada le haghaidh insteallta Piolla brataithe le scannán |
J05AJ04 |
20.9.2023 |
||
|
15.9.2023 |
Enrylaze |
crisantaspase |
|
EU/1/23/1747 |
Solution for injection or infusion |
L01XX02 |
21.9.2023 |
||
|
15.9.2023 |
Inaqovi |
decitabine / cedazuridine |
|
EU/1/23/1756 |
Piolla brataithe le scannán |
L01BC58 |
18.9.2023 |
||
|
15.9.2023 |
Litfulo |
ritlecitinib |
|
EU/1/23/1755 |
Capsúl, crua |
L04AF08 |
18.9.2023 |
||
|
15.9.2023 |
Lyfnua |
gefapixant |
|
EU/1/21/1613 |
Piolla brataithe le scannán |
R05DB29 |
20.9.2023 |
||
|
15.9.2023 |
ORSERDU |
elacestrant |
|
EU/1/23/1757 |
Piolla brataithe le scannán |
L02BA04 |
18.9.2023 |
||
|
15.9.2023 |
Tevimbra |
|
|
EU/1/23/1758 |
Tiúchán do thuaslagán le haghaidh insilte |
L01FF09 |
19.9.2023 |
||
|
15.9.2023 |
Tyenne |
tocilizumab |
|
EU/1/23/1754 |
Tiúchán do thuaslagán le haghaidh insilte Tuaslagán le haghaidh insteallta |
L04AC07 |
18.9.2023 |
||
|
15.9.2023 |
Yesafili |
aflibercept |
|
EU/1/23/1751 |
Solution for injection in a vial |
S01LA05 |
19.9.2023 |
||
|
22.9.2023 |
Tepkinly |
epcoritamab |
|
EU/1/23/1759 |
Tuaslagán le haghaidh insteallta |
Pending |
25.9.2023 |
||
|
22.9.2023 |
Tyruko |
natalizumab |
|
EU/1/23/1745 |
Tiúchán do thuaslagán le haghaidh insilte |
L04AA23 |
25.9.2023 |
||
|
29.9.2023 |
Degarelix Accord |
degarelix acetate |
|
EU/1/23/1753 |
Púdar agus tuaslagóir do thuaslagán le haghaidh insteallta |
L02BX02 |
3.10.2023 |
— Údarú margaíochta a mhodhnú (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
1.9.2023 |
Adcirca |
|
EU/1/08/476 |
4.9.2023 |
||
|
1.9.2023 |
Adtralza |
|
EU/1/21/1554 |
7.9.2023 |
||
|
1.9.2023 |
Emgality |
|
EU/1/18/1330 |
4.9.2023 |
||
|
1.9.2023 |
Ninlaro |
|
EU/1/16/1094 |
4.9.2023 |
||
|
1.9.2023 |
Poteligeo |
|
EU/1/18/1335 |
19.9.2023 |
||
|
11.9.2023 |
Apealea |
|
EU/1/18/1292 |
12.9.2023 |
||
|
11.9.2023 |
Eylea |
|
EU/1/12/797 |
12.9.2023 |
||
|
11.9.2023 |
Fulphila |
|
EU/1/18/1329 |
12.9.2023 |
||
|
11.9.2023 |
GHRYVELIN |
|
EU/1/18/1337 |
15.9.2023 |
||
|
11.9.2023 |
Imlygic |
|
EU/1/15/1064 |
13.9.2023 |
||
|
11.9.2023 |
Insuman |
|
EU/1/97/030 |
12.9.2023 |
||
|
11.9.2023 |
Irbesartan Zentiva |
|
EU/1/06/376 |
14.9.2023 |
||
|
11.9.2023 |
Kaletra |
|
EU/1/01/172 |
12.9.2023 |
||
|
11.9.2023 |
Lumeblue |
|
EU/1/20/1470 |
12.9.2023 |
||
|
11.9.2023 |
OKEDI |
|
EU/1/21/1621 |
12.9.2023 |
||
|
11.9.2023 |
Opatanol |
|
EU/1/02/217 |
12.9.2023 |
||
|
11.9.2023 |
Rybrevant |
|
EU/1/21/1594 |
12.9.2023 |
||
|
11.9.2023 |
Vimizim |
|
EU/1/14/914 |
12.9.2023 |
||
|
12.9.2023 |
Fulphila |
|
EU/1/18/1329 |
14.9.2023 |
||
|
15.9.2023 |
Afinitor |
|
EU/1/09/538 |
18.9.2023 |
||
|
15.9.2023 |
Amlodipine/Valsartan Mylan |
|
EU/1/16/1092 |
18.9.2023 |
||
|
15.9.2023 |
Bevespi Aerosphere |
|
EU/1/18/1339 |
22.9.2023 |
||
|
15.9.2023 |
Celsentri |
|
EU/1/07/418 |
21.9.2023 |
||
|
15.9.2023 |
Clopidogrel Teva |
|
EU/1/09/540 |
18.9.2023 |
||
|
15.9.2023 |
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan |
|
EU/1/17/1222 |
18.9.2023 |
||
|
15.9.2023 |
Esperoct |
|
EU/1/19/1374 |
21.9.2023 |
||
|
15.9.2023 |
Fortacin |
|
EU/1/13/881 |
21.9.2023 |
||
|
15.9.2023 |
GAVRETO |
|
EU/1/21/1555 |
18.9.2023 |
||
|
15.9.2023 |
Grepid |
|
EU/1/09/535 |
18.9.2023 |
||
|
15.9.2023 |
Hizentra |
|
EU/1/11/687 |
21.9.2023 |
||
|
15.9.2023 |
IMBRUVICA |
|
EU/1/14/945 |
18.9.2023 |
||
|
15.9.2023 |
Instanyl |
|
EU/1/09/531 |
22.9.2023 |
||
|
15.9.2023 |
Irbesartan / Hydrochlorothiazide Teva |
|
EU/1/09/583 |
19.9.2023 |
||
|
15.9.2023 |
Iressa |
|
EU/1/09/526 |
18.9.2023 |
||
|
15.9.2023 |
Jinarc |
|
EU/1/15/1000 |
18.9.2023 |
||
|
15.9.2023 |
Kadcyla |
|
EU/1/13/885 |
18.9.2023 |
||
|
15.9.2023 |
Kinzalkomb |
|
EU/1/02/214 |
18.9.2023 |
||
|
15.9.2023 |
Kiovig |
|
EU/1/05/329 |
21.9.2023 |
||
|
15.9.2023 |
Levetiracetam Hospira |
|
EU/1/13/889 |
18.9.2023 |
||
|
15.9.2023 |
MicardisPlus |
|
EU/1/02/213 |
21.9.2023 |
||
|
15.9.2023 |
M-M-RVAXPRO |
|
EU/1/06/337 |
18.9.2023 |
||
|
15.9.2023 |
Olumiant |
|
EU/1/16/1170 |
18.9.2023 |
||
|
15.9.2023 |
Orgovyx |
|
EU/1/22/1642 |
18.9.2023 |
||
|
15.9.2023 |
Pregabalin Sandoz GmbH |
|
EU/1/15/1012 |
18.9.2023 |
||
|
15.9.2023 |
Prolia |
|
EU/1/10/618 |
18.9.2023 |
||
|
15.9.2023 |
Remsima |
|
EU/1/13/853 |
18.9.2023 |
||
|
15.9.2023 |
Sitagliptin/Metformin hydrochloride Accord |
|
EU/1/22/1661 |
18.9.2023 |
||
|
15.9.2023 |
Spevigo |
|
EU/1/22/1688 |
18.9.2023 |
||
|
15.9.2023 |
Spikevax |
|
EU/1/20/1507 |
15.9.2023 |
||
|
15.9.2023 |
Sugammadex Mylan |
|
EU/1/21/1583 |
19.9.2023 |
||
|
15.9.2023 |
Tecfidera |
|
EU/1/13/837 |
19.9.2023 |
||
|
15.9.2023 |
Tenkasi |
|
EU/1/15/989 |
18.9.2023 |
||
|
15.9.2023 |
Tezspire |
|
EU/1/22/1677 |
18.9.2023 |
||
|
15.9.2023 |
Toviaz |
|
EU/1/07/386 |
18.9.2023 |
||
|
15.9.2023 |
Tygacil |
|
EU/1/06/336 |
18.9.2023 |
||
|
15.9.2023 |
Vantobra |
|
EU/1/18/1350 |
19.9.2023 |
||
|
15.9.2023 |
Vaxzevria |
|
EU/1/21/1529 |
18.9.2023 |
||
|
15.9.2023 |
Viagra |
|
EU/1/98/077 |
26.9.2023 |
||
|
15.9.2023 |
Vyvgart |
|
EU/1/22/1674 |
20.9.2023 |
||
|
15.9.2023 |
Xofigo |
|
EU/1/13/873 |
18.9.2023 |
||
|
15.9.2023 |
Zytiga |
|
EU/1/11/714 |
18.9.2023 |
||
|
18.9.2023 |
Rydapt |
|
EU/1/17/1218 |
20.9.2023 |
||
|
22.9.2023 |
Ciambra |
|
EU/1/15/1055 |
25.9.2023 |
||
|
22.9.2023 |
Clopidogrel/Acetylsalicylic acid Mylan |
|
EU/1/19/1395 |
25.9.2023 |
||
|
22.9.2023 |
Erleada |
|
EU/1/18/1342 |
25.9.2023 |
||
|
22.9.2023 |
Imcivree |
|
EU/1/21/1564 |
26.9.2023 |
||
|
22.9.2023 |
Imvanex |
|
EU/1/13/855 |
5.10.2023 |
||
|
22.9.2023 |
Kesimpta |
|
EU/1/21/1532 |
3.10.2023 |
||
|
22.9.2023 |
Myozyme |
|
EU/1/06/333 |
28.9.2023 |
||
|
22.9.2023 |
Ranivisio |
|
EU/1/22/1673 |
25.9.2023 |
||
|
22.9.2023 |
Sunosi |
|
EU/1/19/1408 |
25.9.2023 |
||
|
22.9.2023 |
TAVLESSE |
|
EU/1/19/1405 |
27.9.2023 |
||
|
22.9.2023 |
Vaxchora |
|
EU/1/20/1423 |
25.9.2023 |
||
|
22.9.2023 |
Vildagliptin/Metformin hydrochloride Accord |
|
EU/1/21/1611 |
26.9.2023 |
— Údarú margaíochta a tharraingt siar (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle)
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
11.9.2023 |
Lenalidomide Krka d.d. Novo mesto |
|
EU/1/20/1520 |
14.9.2023 |
||
|
11.9.2023 |
Pandemic influenza vaccine H5N1 BAXTER |
|
EU/1/09/571 |
15.9.2023 |
— Údarú margaíochta a eisiúint (Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle; Airteagal 5 de Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
ANI (an tAinm Neamhdhílseánaigh Idirnáisiúnta) |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Foirm chógaisíochta |
An Cód CAT (an Cód Ceimiceach Teiripeach Anatamaíoch) |
Dáta an fhógra |
||
|
11.9.2023 |
YURVAC RHD |
Galar haemorrhagic coinín agus vacsaín RHDV2 (athchuingreach) |
|
EU/2/23/298 |
Eibleacht le haghaidh insteallta |
QI08AV |
12.9.2023 |
— Údarú margaíochta a mhodhnú (Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle; Airteagal 5 de Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
11.9.2023 |
Apoquel |
|
EU/2/13/154 |
12.9.2023 |
||
|
11.9.2023 |
Prolevare |
|
EU/2/23/295 |
12.9.2023 |
Aon duine ar mian leis féachaint ar an tuarascáil mheasúnaithe phoiblí maidir leis na táirgí íocshláinte atá i gceist agus na cinntí a bhaineann léi, iarrtar orthu teagmháil a dhéanamh le:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |
ELI: http://data.europa.eu/eli/C/2023/298/oj
ISSN 1977-107X (electronic edition)